Dayenne G. van Leeuwen

Author

Memorial Sloan Kettering Cancer Center

Also Known As

D G van Leeuwen, Dayenne Giovanna van Leeuwen, Dayenne G van Leeuwen, Dayenne G. van Leeuwen

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University Texas Children's Hospital Baylor College of Medicine

About

Dayenne G. van Leeuwen is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	1.5K
2	Cell Biology	4	4	1.5K
3	Immunology	4	4	1.5K
4	Autoimmunity	2	2	466
5	Health Sciences	1	1	316

Dayenne G. van Leeuwen

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo Sarwish Rafiq, Oladapo Yeku, Hollie J. Jackson, Nature Biotechnology Cancer ImmunosurveillancePd-1-blocking ScfvImmunologyTumor ImmunityImmune Checkpoint Inhibitor	2018	801
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System Mauro P. Avanzi, Oladapo Yeku, Xinghuo Li, Cell Reports Endogenous Immune SystemT-regulatory CellImmunologyImmune Cell TherapyImmunotherapy	2018	316
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response Nicholas F. Kuhn, Terence J. Purdon, Dayenne G. van Leeuwen, Cancer Cell Tumor ImmunologyCancer ImmunosurveillanceMedicineImmunologyAntigen Processing	2019	230
Enhancing Antitumor Efficacy of Chimeric Antigen Receptor T Cells Through Constitutive CD40L Expression Kevin J. Curran, Beatrijs A. Seinstra, Yan Nikhamin, Molecular Therapy	2015	211
IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia Hollie J. Pegram, Terence J. Purdon, Dayenne G. van Leeuwen, Leukemia Hematological MalignancyImmunologyHematologyAutoimmunityAdult T-cell Leukemia-lymphoma	2014	150
Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL Mark B. Geyer, Isabelle Rivière, Brigitte Sénéchal, JCI Insight	2019	98
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T cells for T cell malignancies Norihiro Watanabe, Feiyan Mo, Rong Zheng, Molecular Therapy	2022	69
IL-18 Secreting CAR T Cells Enhance Cell Persistence, Induce Prolonged B Cell Aplasia and Eradicate CD19+ Tumor Cells without Need for Prior Conditioning Mauro P. Avanzi, Dayenne G. van Leeuwen, Xinghuo Li, Blood	2016	29
Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity Royce Ma, Mae Woods, Phillip M. Burkhardt, Cell Reports Medicine	2024	11

Page 1